Dementia with Lewy Bodies
Diseases such as Alzheimer’s disease, dry AMD, Parkinson’s disease, Huntington’s disease and dementia with Lewy bodies are characterized by an accumulation of toxic proteins and a failure in the processes responsible for degrading them. While the proteins may differ between the diseases (Aβ, α-synuclein, huntingtin proteins in the cases of Alzheimer’s, Parkinson’s and Huntington’s diseases, respectively) Cognition believes that displacing toxic forms of these proteins and regulating cellular damage response mechanisms may restore these systems to a functioning state, providing a disease-modifying therapeutic benefit to patients.
Cognition has identified several structurally unique compounds that each possess unique advantages for specific disease indications and patient populations. Currently, several of our lead molecules are being assessed as potential IND candidates in various indications.
Cognition’s lead candidate, CT1812, was one of many compounds identified using a specific screening process.
Cognition’s screening approach employs in vitro culture systems, assays and medicinal chemistry compound libraries. At its foundation, Cognition uses primary cell-based models to screen compounds in the target cell population itself (neurons and glia), as opposed to artificially engineered cells or stem cells that do not completely replicate the complex function of the mature brain cells.
Cognition uses screening assays that measure basic cellular functions such as lipid trafficking and autophagy that are sensitive to age-related insults (protein aggregates or oxidative stress) prominent in neurodegenerative diseases. Compounds identified to alleviate this stress are then progressed to assays that measure aspects of neuronal function such as synaptic protein expression and number.